Rapamycin increases grip strength and attenuates age-related decline in maximal running distance in old low capacity runner rats

Rapamycin is known to extend lifespan. We conducted a randomized placebo-controlled study of enteric rapamycin-treatment to evaluate its effect on physical function in old low capacity runner (LCR) rats, a rat model selected from diverse genetic background for low intrinsic aerobic exercise capacity without genomic manipulation and characterized by increased complex disease risks and aging phenotypes. The study was performed in 12 male and 16 female LCR rats aged 16-22 months at baseline. The treatment group was fed with rapamycin-containing diet pellets at approximately 2.24mg/kg body weight per day and the placebo group with the same diet without rapamycin for six months. Observation was extended for additional 2 months. Physical function measurements include grip strength measured as maximum tensile force using a rat grip strength meter and maximum running distance (MRD) using rat physical treadmill test. The results showed that rapamycin improved grip strength by 13% (p=.036) and 60% (p<.001) from its baseline in female and male rats, respectively. Rapamycin attenuated MRD decline by 66% (p<.001) and 46% (p=.319) in females and males, respectively. These findings provide initial evidence for beneficial effect of rapamycin on physical functioning in an aging rat model of high disease risks with significant implication in humans.

[1]  Emma L. Baar,et al.  Sex‐ and tissue‐specific changes in mTOR signaling with age in C57BL/6J mice , 2015, Aging cell.

[2]  L. Geddes.  The end of disease , 2016 .

[3]  S. Austad,et al.  Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life , 2015, PloS one.

[4]  M. Blagosklonny,et al.  Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats , 2015, Oncotarget.

[5]  M. Blagosklonny.  Rejuvenating immunity: “anti-aging drug today” eight years later , 2015, Oncotarget.

[6]  J. Praestgaard,et al.  mTOR inhibition improves immune function in the elderly , 2014, Science Translational Medicine.

[7]  M. Blagosklonny,et al.  Comparison of rapamycin schedules in mice on high-fat diet , 2014, Cell cycle.

[8]  M. Blagosklonny,et al.  Fasting levels of hepatic p-S6 are increased in old mice , 2014, Cell cycle.

[9]  F. Neff,et al.  Longevity, aging and rapamycin , 2014, Cellular and Molecular Life Sciences.

[10]  P. Froguel,et al.  Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice , 2014, PloS one.

[11]  M. Blagosklonny,et al.  Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet , 2014, Aging cell.

[12]  Z. D. Sharp,et al.  Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.

[13]  S. Austad,et al.  Rapamycin extends life and health in C57BL/6 mice. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[14]  K. Budde,et al.  Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation , 2013, Transplantation.

[15]  H. Fuchs,et al.  Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.

[16]  M. Blagosklonny.  Rapamycin extends life- and health span because it slows aging , 2013, Aging.

[17]  Lan Ye,et al.  Rapalogs and mTOR inhibitors as anti-aging therapeutics. , 2013, The Journal of clinical investigation.

[18]  M. Blagosklonny,et al.  Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet , 2013, Cell Death and Disease.

[19]  M. Maze,et al.  Dysfunction of Inflammation-Resolving Pathways Is Associated with Exaggerated Postoperative Cognitive Decline in a Rat Model of the Metabolic Syndrome , 2012, Molecular medicine.

[20]  M. Blagosklonny,et al.  Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging , 2012, Aging.

[21]  L. Koch,et al.  Rats Bred for Low Aerobic Capacity Become Promptly Fatigued and Have Slow Metabolic Recovery after Stimulated, Maximal Muscle Contractions , 2012, PloS one.

[22]  Y. Jan,et al.  Rapamycin Ameliorates Age-Dependent Obesity Associated with Increased mTOR Signaling in Hypothalamic POMC Neurons , 2012, Neuron.

[23]  M. Blagosklonny.  Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to , 2012, Aging.

[24]  M. Blagosklonny.  Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging , 2012, Aging.

[25]  U. Wisløff,et al.  A rat model system to study complex disease risks, fitness, aging, and longevity. , 2012, Trends in cardiovascular medicine.

[26]  Godfrey L. Smith,et al.  Intrinsic Aerobic Capacity Sets a Divide for Aging and Longevity , 2011, Circulation research.

[27]  Stephanie A. Studenski,et al.  Comparative effectiveness research and patients with multiple chronic conditions. , 2011, The New England journal of medicine.

[28]  A. Brenner,et al.  Common toxicities of mammalian target of rapamycin inhibitors , 2011, Targeted Oncology.

[29]  Steven L Britton,et al.  Low intrinsic running capacity is associated with reduced skeletal muscle substrate oxidation and lower mitochondrial content in white skeletal muscle. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[31]  H. Hsu,et al.  Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. , 2009, Basic & clinical pharmacology & toxicology.

[32]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[33]  R. A. Howlett,et al.  Peripheral oxygen transport and utilization in rats following continued selective breeding for endurance running capacity. , 2009, Journal of applied physiology.

[34]  Geng-Ruei Chang,et al.  Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. , 2009, Journal of pharmacological sciences.

[35]  J. Rovira,et al.  Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[36]  K. Becker,et al.  The physical and biological characterization of a frail mouse model. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[37]  M. Tinetti,et al.  The end of the disease era. , 2004, The American journal of medicine.

[38]  L. Koch,et al.  Artificial selection for intrinsic aerobic endurance running capacity in rats. , 2001, Physiological genomics.

[39]  K. Nair,et al.  Age-related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. , 1998, The Journal of nutrition.

[40]  C. Hansen,et al.  Development of the National Institutes of Health genetically heterogeneous rat stock. , 1984, Alcoholism, clinical and experimental research.

[41]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[42]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .